Final patient-reported outcomes (PROs) in unselected men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as initial treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from the phase 3 TALAPRO-2 study. | Publicación